Avacopan ADVOCATE Study Design
Much has already been written in recent months about avacopan / TAVNEOS, the oral complement C5a receptor antagonist. It is in the news because of the way the parent company, Chemocentryx, its Adjudication Board and the CRO handled the unblinded data and ‘re-adjudicated’ the results to achieve the desired outcome, an Continue reading Avacopan ADVOCATE Study Design